Veraxa Biotech Holding AG (VRXA)
$1.20+5.26%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $170M
- Beta
- 0.26
- Short % float
- 1.86%
- Days to cover
- 4.6
- SI change
- +12.1%
- 1W
- +11.11%
- 1M
- -26.38%
- vs SPY 1W
- +11.25%
- vs SPY 1M
- -28.89%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-
---
[VALUATION]
P/E TTM-
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-
P/FCF-
EV/EBITDA-
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO-
ND/EBITDA-
BETA0.26
Company news
FAQ
- What is LOPJLB’s current signal on VRXA?
- LOPJLB’s latest quantitative signal on Veraxa Biotech Holding AG (VRXA) is SELL. Signals are updated daily.
- What market regime is VRXA in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Veraxa Biotech Holding AG (VRXA) do?
- Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, wit…